As a Free StocksGuide user, you can view scores for all 7,040 stocks worldwide.
12 Analysts have issued a BioXcel Therapeutics, Inc. forecast:
12 Analysts have issued a BioXcel Therapeutics, Inc. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 0.87 0.87 |
64%
64%
|
|
| Gross Profit | -1.26 -1.26 |
221%
221%
|
|
| EBITDA | -50 -50 |
52%
52%
|
|
| EBIT (Operating Income) EBIT | -50 -50 |
52%
52%
|
|
| Net Profit | -51 -51 |
53%
53%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
| Head office | United States |
| CEO | Vimal Mehta |
| Employees | 37 |
| Founded | 2017 |
| Website | www.bioxceltherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


